Friday, Of January The 27 Of 2006
To personalize Drugs Of the Depression
The new genetic tests conserve help doctors select the best medication for each patient.
By Emily Singer
The people diagnosed with the clinical depression in front of do a rough way to the recovery. Many spend weeks, months, or still the years that try diverse antidepressants in hopes to find the medication right -- one that cures its depression without insomnia, headaches, or other indirect effect.
Now two new classes of genetic tests, one already available and several years of absentee, could help to doctors and patients to avoid this process wearisome.
"it is very difficult to have to take a drug per weeks, later to obtain of her and to try a new one," says to Julio Licinio, siquiatra that it studies the genetics of the depression in the university of California, the Angels. "if we had any class of marker that said to us what person would respond what drugs, treatment is much more efficient that now is."
Siquiatras in the United States was able recently a new system of tools to match the drug to the patient: genetic tests that they can predict if a person has indirect effect with a particular drug.
One such, tested by the Swiss-based diagnosis of Roche, was approved by the administration of the food and the drug of the United States in January of 2005 and recently put to disposition the doctors. The test of Roche detects the genetic variants for two enzymes implied in analyzes of 25 percents of drugs of the prescription, including medications of the pain, of betabloqueadores, and antidepressants. Somebody that has a form of the enzyme that it analyzes a drug slowly is more probable to experience indirect effect in the standard dose because the drug is accumulated in the body. In the other end, somebody that has a form of the enzyme that analyzes the drug very quickly can not have the medicine in the body enough time to make its work.
 [ chasque here for vision an image of the probador of Roche. ]
The experts predict that one of the applications potential main for the test will be in the depression that treats, because people react so variable to diverse antidepressants, and the indirect effect are one of the shutdown of the people of the main reasons these drugs.
This test is one of the first attempts to take to the customized medication the clinic, "says to Jose of Leon, siquiatra in the university of Kentucky in Lexington, that is studying the effectiveness of these tests. Specifically, it found that people with a mutation in one of these enzymes were more probable to stop taking from risperidone of the drug, antipsychotic, due to injurious effects. He now is working with Roche to see how he is efficient and profitable the tests are in psychiatric hospitals.